# EDGAR Filing Document

**Accession Number:** 0001910264
**File Stem:** 0001104659-25-084832
**Filing Date:** 2025-8
**Character Count:** 9622
**Document Hash:** 4dcf9762693fa75db9028545c206745e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-084832.hdr.sgml**: 20250828

**ACCESSION NUMBER**: 0001104659-25-084832

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250828

**EFFECTIVENESS DATE**: 20250828

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SR ONE CAPITAL MANAGEMENT, LP
- **CENTRAL INDEX KEY:** 0001910264

**ORGANIZATION NAME:**
- **EIN:** 843397640
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-21964
- **FILM NUMBER:** 251274490

**BUSINESS ADDRESS:**
- **STREET 1:** 985 OLD EAGLE SCHOOL ROAD
- **STREET 2:** SUITE 511
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (610) 766-2240

**MAIL ADDRESS:**
- **STREET 1:** 985 OLD EAGLE SCHOOL ROAD
- **STREET 2:** SUITE 511
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001910264

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** SR ONE CAPITAL MANAGEMENT, LP

**Address:** 985 Old Eagle School Road, Wayne, PA 19087

**Telephone number:** 410-800-7503

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-21964

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER         | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                           | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Arcellx, Inc.          | 03940C100 | 05/28/2025     | Advisory Vote for Executive Compensation                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        2346630 |                0 | FOR         |                                  2346630 | FOR                         |  |
| Crispr Therapeutics AG | H17182108 | 06/05/2025     | Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders | SECTION 14A SAY-ON-PAY VOTES |        1048951 |                0 | FOR         |                                  1048951 | FOR                         |  |
| Crispr Therapeutics AG | H17182108 | 06/05/2025     | Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders                               | SECTION 14A SAY-ON-PAY VOTES |        1048951 |                0 | FOR         |                                  1048951 | FOR                         |  |
| Crispr Therapeutics AG | H17182108 | 06/05/2025     | Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2025 to June 30, 2026                                                     | SECTION 14A SAY-ON-PAY VOTES |        1048951 |                0 | FOR         |                                  1048951 | FOR                         |  |
| Crispr Therapeutics AG | H17182108 | 06/05/2025     | Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2025                                                         | SECTION 14A SAY-ON-PAY VOTES |        1048951 |                0 | FOR         |                                  1048951 | FOR                         |  |
| Crispr Therapeutics AG | H17182108 | 06/05/2025     | Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders                              | SECTION 14A SAY-ON-PAY VOTES |        1048951 |                0 | FOR         |                                  1048951 | FOR                         |  |
| Crispr Therapeutics AG | H17182108 | 06/05/2025     | Non-binding advisory vote on the 2024 Compensation Report                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |        1048951 |                0 | FOR         |                                  1048951 | FOR                         |  |
| Crispr Therapeutics AG | H17182108 | 06/05/2025     | Non-Binding Advisory Vote on the Compensation Paid to the Company's Named Executive Officers Under U.S. Securities Law Requirements                                                        | SECTION 14A SAY-ON-PAY VOTES |        1048951 |                0 | FOR         |                                  1048951 | FOR                         |  |
| Oculis Holding AG      | H5870P102 | 06/04/2025     | Vote on Total Fixed (Non-Performance-Related) Compensation for Non-Executive Members of the Board of Directors until the end of the Company's 2026 Annual General Meeting                  | SECTION 14A SAY-ON-PAY VOTES |         322500 |                0 | FOR         |                                   322500 | FOR                         |  |
| Oculis Holding AG      | H5870P102 | 06/04/2025     | Vote on Equity or Equity Based Compensation for Non-Executive Members of the Board of Directors until the end of the Company's 2026 Annual General Meeting                                 | SECTION 14A SAY-ON-PAY VOTES |         322500 |                0 | FOR         |                                   322500 | FOR                         |  |
| Oculis Holding AG      | H5870P102 | 06/04/2025     | Vote on Fixed (Non-Performance-Related) Compensation for Members of the Executive Committee payable in 2026                                                                                | SECTION 14A SAY-ON-PAY VOTES |         322500 |                0 | FOR         |                                   322500 | FOR                         |  |
| Oculis Holding AG      | H5870P102 | 06/04/2025     | Vote on variable Compensation for Members of the Executive Committee payable in 2026                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |         322500 |                0 | FOR         |                                   322500 | FOR                         |  |
| Oculis Holding AG      | H5870P102 | 06/04/2025     | Vote on Equity Based Compensation for Members of the Executive Committee for 2026                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |         322500 |                0 | FOR         |                                   322500 | FOR                         |  |
| Oculis Holding AG      | H5870P102 | 06/04/2025     | Non-Binding Advisory Vote on the 2024 Compensation Report                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         322500 |                0 | FOR         |                                   322500 | FOR                         |  |
| Oruka Therapeutics     | 687604108 | 06/02/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         430330 |                0 | FOR         |                                   430330 | FOR                         |  |
| Oruka Therapeutics     | 687604108 | 06/02/2025     | To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers                                              | SECTION 14A SAY-ON-PAY VOTES |         430330 |                0 | FOR         |                                   430330 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** SR ONE CAPITAL MANAGEMENT, LP

**By (Signature):** Sasha Keough

**By (Printed Signature):** Sasha Keough

**By (Title):** General Counsel and CCO

**Date:** 08/28/2025